The incidence of prostate cancer in Iran: Results of a population-based cancer registry by Sadjadi, A. et al.
  
 
 
Arch Iranian Med 2007; 10 (4): 481 – 485
Original Article 
 
 
 
 
 
 
 
  
  
  
 
  
 
  
 
   
 
 
  
 
 
  
 
 
  
 
 
 
 
 
 
 
  
 
The Incidence of Prostate Cancer in Iran: Results of a  

Population-Based Cancer Registry 

Alireza Sadjadi MD•*, Mehdi Nooraie MD*, Anahita Ghorbani MD*, 

Masoomeh Alimohammadian MSc**, Mohammad-Javad Zahedi MD***,  

Sodeif Darvish-Moghadam MD***, Hafez Fakheri MD†, Masood Babai MD‡, 

Shahriar Semnani MD§, Fariborz Mansour-Ghanaei MD║, Mohammad-Ali Mohagheghi MD#
 
Background: Little is known about the epidemiology of prostate cancer in Iranian men. We
carried out an active prostate cancer surveillance program in five provinces of Iran.  
Methods: Data used in this study were obtained from population-based cancer registries
between 1996 and 2000. 
Results: The age-standardized incidence rate of prostate carcinoma in the five provinces was 
5.1 per 100,000 person-years. No significant difference was seen in the age-standardized incidence
rate of prostate cancer within the provinces studied. The mean±SD age of patients with prostate
cancer was 67±13.5 years. 
Conclusion: The incidence of prostate cancer in Iran is very low as compared to the Western
countries.  This can partly be explained by lack of nationwide screening program, younger age 
structure and quality of cancer registration system in Iran.
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Introduction 
 
he latest estimates of global cancer 
incidence show that prostate cancer has 
become the second most common cancer 
among men in the world, accounting for almost 
11.7% of new cancer cases overall, which 
constitutes 19% of cancers in developed countries 
and 5.3% in developing countries.1 The annual 
incidence of prostate cancer has grown up in many 
different countries.1 – 5 In some countries such as in 
the U.S., prostate surpassed lung as the most 
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frequent cancer site among men.1, 6, 7 Prostate 
cancer alone accounts for 33% of incident cases in
2men.
Epidemiologic studies revealed that there are
variations in the geographic and racial distribution
of cancer of prostate.8 – 10 The incidence is low in
Asia (3 – 8 per 100,000 men per year), 
intermediate in Africa and Eastern Europe, and 
high in Western Europe and North America.11 
The incidence of prostate cancer grows up with 
the increase of age8 with three-quarters of all cases
occurring in men aged 65 years or more.1 
Some previous studies have shown that in
contrast to Europe and America, prostate 
carcinoma is not common in Iran.12 It has been also
shown that the incidence of prostate cancer has
increased in Iranian immigrants to Western 
countries.13 
Current data on the epidemiology of prostate
cancer in Iran are scarce and incomplete. The
present paper provides the first population-based 
report on prostate cancer incidence rate in Iran 
based on data obtained from cancer registries
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covering five provinces of Iran.  
 
Patients and Methods 
 
The study design and data collection strategies 
have been described previously.14 In summary, 
incidence data were obtained from population-
based cancer registries located in five provinces of 
Iran, namely Ardabil, Guilan, Golestan,
Mazandaran, and Kerman, which consisted of a 
population of almost 10 million. Data of all 
patients with prostate cancer in these provinces 
were collected for a period of five years from 1996 
to 2000.  
After being confirmed according to the 
inclusion criteria, the data were then summarized 
in a data sheets and coded using the ICD-O, 3rd  
edition. The alphabetically ordered data were 
checked for repeated cases by manual and 
computerized linkage. The data were then 
computerized using the SPSS 10.0 and MS Excel 
software with Persian fonts for the analysis. We 
calculated person-years of the population at risk 
using each year method. The crude (all-ages) and 
age-specific rates per 100,000 person-years for all 
provinces were calculated separately. For each 
province, an average annual age-standardized 
incidence rates (ASR) per 100,000 person-years 
were computed by the direct method using the 
World Standard Population:  
ASR = ∑ai wi ∑wi  
i=1 i=1 
where ai is age-specific incidence rate of each age 
group, and wi is world standard population of each 
age group.15  Similarly, the standard error (SE) was 
calculated as follows: 
⎛ ⎞2 SE = ∑[a i wi (100,000 − a i ) ni ] ⎜∑w i ⎟  
i=1 ⎝ i=1 ⎠ 
where ai is age-specific incidence rate of each age 
group, wi is world standard population of each age 
group, and ni represents person-years in each age 
group, for each province and for all the provinces 
as a whole providing a summary comparison 
statistics. The directly age-standardized rate for 
each province was compared with that for the rest 
of the provinces, using standardized rate ratios 
(according to ASR and SE of each province in 
comparison with those of the rest). The statistical 
significance of each ratio was calculated and 
reported whether each province’s ASR was 
significantly different (higher or lower) at the 5% 
level from the rate for the rest of provinces.15   
 
Results 
 
There were 703 new cases of prostate cancer 
recorded in the five cancer registries during the 
five-year period of 1996 to 2000. Age-specific, 
crude and age-standardized incidence rates of 
prostate cancer in the five provinces are depicted in 
Table 1. According to these data, the ASR of 
prostate cancer in the five provinces was calculated 
to be 5.1 per 100,000 person-years. The mean±SD 
age of patients with prostate cancer at the time of 
diagnosis was 67±13.5 years. Half of prostate 
cancers were observed in patients aged 70 years or 
over. Figure 1 shows the logarithms of the prostate 
cancer incidence rates in the five provinces as a 
whole plotted against the logarithms of the age 
groups (from 25 – 74 years). There were no 
statistically significant differences in ASR of 
prostate cancer among these five provinces 
(P>0.05). 
 
Discussion  
 
Prostate cancer has become an increasingly 
important health problem worldwide.16   
Considering the incidence of prostate cancer 
has risen dramatically over the last decades,3 it is 
currently one of the most common
  
 
 
 
            
            
            
Province Cases affected 0 - 14 
Age-specific rate in age group (yr) 
15 - 24 25 - 34 35 - 44 45 - 54 55-64 ≥65 
Crude
rate ASR SE 
Ardabil 58 0 0 0 1 2.5 7.9 34.8 2.2 3.4 0.47
Guilan 182 0 0.3 0.1 0 1.1 9.9 50 3.6 4.4 0.33
Mazandaran 237 0.7 0 0.2 0.9 3.3 12.2 62.5 5.5 6.1 0.46 
Golestan 106 0 0.2 0.2 0 2.3 10.1 57.7 3.2 5.2 0.49 
Kerman 120 0 0 0.2 0.4 0.8 8.9 32.8 2.4 3.2 0.35 
Total 703 0.1 0.2 0.2 0.3 2.2 11.3 55 4.1 5.1 0.37
Table 1. Crude, age-specific, and age-standardized incidence rates (per 100,000 person-years) of prostate cancer in
five provinces in Iran between 1996 and 2000
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Figure 1. Changes in incidence with age for cancer of
prostate. 
malignancies around the world.17 Wide variations 
in the incidence of clinical prostate cancer have
been reported between different ethnic groups and 
among different populations.8 To date, there has 
been no population-based study on the incidence of
prostate cancer in Iran. This paper reveals the first 
report of an active prostate cancer surveillance 
program carried out in five provinces of Iran.  
Our data indicate no statistically significant 
variations in the ASR of prostate cancer in these 
five provinces. This finding can be explicable in 
terms of similar prevalence of the probable
environmental and genetic risk factors promoting 
prostate cancer in these provinces.18 
2,10As demonstrated in Figure the age 
0 
200 
400 
600 
800 
1000 
1200 
0-14 15-
24 
25-
34 
35-
44 
45-
54 
55-
64 
65 
Age groups 
A
ge
-s
pe
ci
fic
 in
ci
de
nc
e 
ra
te
 p
er
 1
00
00
0
USA, Connecticut 
Kuwait 
Iran, five provinces 
China, Shanghai 
Figure 2. Age-specific incidence rate of prostate
cancer in various countries.
incidence curve of prostate cancer in Iran shows a
slow rise with increase of age (after 50 years of 
age). Similar pattern is observed in China and 
Kuwait. By contrast, the USA curve displays a
sharp rise at this age. This sharp pattern may be
due to the establishment of a National screening 
program and consequent detection of even latent 
prostate cancer in the US.19 
Figure 3 shows the ASR of prostate cancer in 
Iranian men in comparison with various 
countries.20 The ASR of prostate cancer in Iran is 
close to that of Asian countries such as China and 
Kuwait.4 Compared with the Western countries
like the US, Iran has a remarkably lower incidence 
rate of prostate cancer.21 This large disparity in the
incidence of prostate cancer may be due to a 
combination of genetic and environmental factors. 
Increased awareness of the condition and 
nationwide prostate screening program can explain  
partly the high incidence rates of prostate cancer 
 22, 23reported in Western countries.2,  Prostate-
specific antigen (PSA) testing for prostate cancer
screening can signal the presence of impalpable
3, 24and thus previously undetectable cancer.
Consequently, intensified effort in early detection 
of prostate cancer through PSA screening has 
amplified the incidence of prostate cancer by
allowing the detection of localized latent cancer 
lesions,9, 25 whereas in our country, data on 
incidence of prostate cancer only reflect the 
clinically obvious diseases. This certainly results 
from shortage in early detecting prostate cancer 
owing to lack of screening program. As prostate 
cancer occur mainly  in higher ages, high life 
expectancy of the male population in Western
countries resulting in greater proportions of elderly
men in their population can also contribute to these 
differences.17, 25, 26 Additionally, other risk factors 
such as high fat Western diet, socioeconomic 
status, smoking, infectious agents, sexual behavior, 
and occupational exposures might play a role.6, 18, 27
– 32 Finally, high quality registration system for 
prostate cancer in Western world can provide the
most accurate data, whereas this is lacking in Iran 
and we have undoubtedly underestimated the 
number of people affected.  
The mean±SD age at diagnosis of prostate
cancer in Iranian men is 67±13.5 years. In fact, 
half of the cases tend to occur over the age of 70. 
Hence, the age distribution of prostate cancer in
Iran is similar to that of other countries around the 
world.1 
As it is expected that prostate cancer incidence 
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Prostate cancer in Iran
rate goes up with increasing age, the drop in 
prostate cancer incidence rate in the age group of 
65 – 69 years (Figure 1) may be due to an
underreporting of cases in elderly Iranian men over 
65 years. 
Previous studies on the multi-stage theory of
carcinogenesis suggest that for cancer of certain 
organs the mortality increases with the sixth power 
of the age.33 They formulate a hypothesis that this
relationship is a result of constant strength of the 
carcinogenic factors within the specified period of
life and independent role of hormonal control in
growth. Divergence of our observations from the 
regression line with a gradient of 6 to 1 exhibits the 
lack of a uniform relationship between incidence 
rates and the sixth power of the age. This is similar 
to the findings of those prior studies, which
suggest the powers of some of the risk factors, i.e.,
hormonal risk factors contributing to the
development of the disease are variable. Indeed, it 
is believed that prostate cancer is strongly
influenced by endocrine secretions especially sex 
hormones which vary in each individual 
throughout the life.33, 34 
A limitation of our study arise from its 
retrospective nature which may lead to an 
underestimation of the actual number of cases in
consequence of poor quality of documenting
medical records especially in private medical
centers. Strength of this study is that data are based 
on population-based cancer registries covering a 
much larger geographic area than what could be
evaluated in the past. 
In view of wide variations reported in the 
incidence of prostate cancer among various
populations even within a given country,16 
expansion of our cancer registration system is 
necessary to identify the true incidence of prostate 
cancer and its probable geographic disparities in
Iran. Furthermore, a screening program for prostate 
cancer by PSA testing is highly recommended in
order to discover latent asymptomatic prostate 
cancer cases and help clarify the real burden of the 
disease. In addition, future investigations are 
needed to improve our knowledge of risk factors 
predisposing to and probable protective factors 
against prostate cancer in Iran and show its trends 
over the time.
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